Evidence map›Paper›PMID 36587850›Full record

ArticleThe Journal of allergy and clinical immunology2023

The gut microbiome is a significant risk factor for future chronic lung disease.

Yang Liu, Shu Mei Teo, Guillaume Méric, Howard H F Tang, Qiyun Zhu, Jon G Sanders, Yoshiki Vázquez-Baeza, Karin Verspoor, Ville A Vartiainen, Pekka Jousilahti and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Potential Benefits of Gut Microbiota Modulation in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yang LiuDepartment of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Australia. Electronic address: yang.liu2@baker.edu.au.
Shu Mei TeoCambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Australia; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
Guillaume MéricCambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Australia.
Howard H F TangCambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Australia; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Qiyun ZhuSchool of Life Sciences, Arizona State University, Tempe, Ariz; Biodesign Center for Fundamental and Applied Microbiomics, Arizona State University, Tempe, Ariz.
Jon G SandersDepartment of Ecology and Evolutionary Biology, Cornell University, Ithaca, NY.
Yoshiki Vázquez-BaezaCenter for Microbiome Innovation, Jacobs School of Engineering, University of California San Diego, La Jolla, Calif.
Karin VerspoorSchool of Computing Technologies, RMIT University, Melbourne, Australia; School of Computing and Information Systems, The University of Melbourne, Melbourne, Australia.
Ville A VartiainenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
Pekka JousilahtiDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Leo LahtiDepartment of Computing, University of Turku, Turku, Finland.
Teemu NiiranenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland; Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland.
Aki S HavulinnaDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland; Institute for Molecular Medicine Finland, FIMM-HiLIFE, University of Helsinki, Helsinki, Finland.
Rob KnightCenter for Microbiome Innovation, Jacobs School of Engineering, University of California San Diego, La Jolla, Calif; Department of Computer Science and Engineering, University of California San Diego, La Jolla, Calif; Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, Calif.
Veikko SalomaaDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Michael InouyeDepartment of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Australia; Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; British Heart Foundation Cambridge Centre of Research Excellence, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom; The Alan Turing Institute, London, United Kingdom; Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom. Electronic address: minouye@baker.edu.au.

Funding

British Heart Foundation RG/13/13/30194British Heart Foundation RG/18/13/33946Chief Scientist OfficeDepartment of Health BRC-1215-20014Medical Research CouncilWellcome Trust
6 · The paper itself

Abstract

backgroundThe gut-lung axis is generally recognized, but there are few large studies of the gut microbiome and incident respiratory disease in adults.

objectiveWe sought to investigate the association and predictive capacity of the gut microbiome for incident asthma and chronic obstructive pulmonary disease (COPD).

methodsShallow metagenomic sequencing was performed for stool samples from a prospective, population-based cohort (FINRISK02; N = 7115 adults) with linked national administrative health register-derived classifications for incident asthma and COPD up to 15 years after baseline. Generalized linear models and Cox regressions were used to assess associations of microbial taxa and diversity with disease occurrence. Predictive models were constructed using machine learning with extreme gradient boosting. Models considered taxa abundances individually and in combination with other risk factors, including sex, age, body mass index, and smoking status.

resultsA total of 695 and 392 statistically significant associations were found between baseline taxonomic groups and incident asthma and COPD, respectively. Gradient boosting decision trees of baseline gut microbiome abundance predicted incident asthma and COPD in the validation data sets with mean area under the curves of 0.608 and 0.780, respectively. Cox analysis showed that the baseline gut microbiome achieved higher predictive performance than individual conventional risk factors, with C-indices of 0.623 for asthma and 0.817 for COPD. The integration of the gut microbiome and conventional risk factors further improved prediction capacities.

conclusionsThe gut microbiome is a significant risk factor for incident asthma and incident COPD and is largely independent of conventional risk factors.

Indexed as

AsthmaGastrointestinal MicrobiomePulmonary Disease, Chronic ObstructiveAdultHumansProspective StudiesRisk FactorsasthmaCOPDGutmetagenomicsmicrobiome

Identifiers

PMID36587850
PMCPMC10109092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.